TAIGEN BIOTECHNOLOGY ANNOUNCES STRATEGIC AGREEMENT WITH PROCTER & GAMBLE

TaiGen Biotechnology has announced the signing of a strategic alliance relationship with Procter & Gamble Pharmaceuticals (P&GP) to further the development and commercialization of a novel non-flourinated quinolone antibiotic, invented by P&GP. Under the terms of the agreement, TaiGen will be responsible for conducting Phase Ib and Phase II development of the compound to meet worldwide regulatory standards.
Yahoo News